tradingkey.logo
tradingkey.logo
Search

Precision BioSciences Inc

DTIL
Add to Watchlist
8.180USD
+0.300+3.81%
Close 07/02, 13:00ETQuotes delayed by 15 min
211.09MMarket Cap
LossP/E TTM

TradingKey Stock Score of Precision BioSciences Inc

Currency: USD Updated: 2026-07-02

Key Insights

Precision BioSciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 48 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 29.60.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Precision BioSciences Inc's Score

Industry at a Glance

Industry Ranking
48 / 387
Overall Ranking
134 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Precision BioSciences Inc Highlights

StrengthsRisks
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Growing
The company is in a growing phase, with the latest annual income totaling USD 34.26M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -3.89, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 15.71M shares, increasing 16.10% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 25.79K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.80.

Analyst Rating

Based on 5 analysts
Strong Buy
Current Rating
29.600
Target Price
+275.63%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Precision BioSciences Inc?

The TradingKey Stock Score provides a comprehensive assessment of Precision BioSciences Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Precision BioSciences Inc’s performance and outlook.

How do we generate the financial health score of Precision BioSciences Inc?

To generate the financial health score of Precision BioSciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Precision BioSciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Precision BioSciences Inc.

How do we generate the company valuation score of Precision BioSciences Inc?

To generate the company valuation score of Precision BioSciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Precision BioSciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Precision BioSciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Precision BioSciences Inc.

How do we generate the earnings forecast score of Precision BioSciences Inc?

To calculate the earnings forecast score of Precision BioSciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Precision BioSciences Inc’s future.

How do we generate the price momentum score of Precision BioSciences Inc?

When generating the price momentum score for Precision BioSciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Precision BioSciences Inc’s prices. A higher score indicates a more stable short-term price trend for Precision BioSciences Inc.

How do we generate the institutional confidence score of Precision BioSciences Inc?

To generate the institutional confidence score of Precision BioSciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Precision BioSciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Precision BioSciences Inc.

How do we generate the risk management score of Precision BioSciences Inc?

To assess the risk management score of Precision BioSciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Precision BioSciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Precision BioSciences Inc.